스타틴이 총 사망률에 미치는 영향
Statin Use and the Risk of All-cause Mortality
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Statins are the cornerstone in primary and secondary prevention of atherosclerotic cardiovascular disease. Most benefits of statin treatment mainly come from lowering low-density lipoprotein cholesterol levels. However, statins have pleiotropic effects on vascular dysfunction, inflammation, and immunomodulation beyond cholesterol-lowering, suggesting a positive impact on various health outcomes. All-cause mortality is a commonly chosen outcome in randomized controlled trials (RCTs) of statins. Nevertheless, the effect of statin treatment on the risk of all-cause mortality remains uncertain since it has usually been evaluated as a secondary outcome or a component of the primary composite outcome. A recent meta-analysis of RCTs also failed to draw a clear conclusion on this issue. Further studies investigating all-cause mortality as a primary endpoint are needed to determine the effect of statins on all-cause mortality from the perspective of evidence-based medicine.
Abstract
Statins are the cornerstone in primary and secondary prevention of atherosclerotic cardiovascular disease. Most benefits of statin treatment mainly come from lowering low-density lipoprotein cholesterol levels. However, statins have pleiotropic effects on vascular dysfunction, inflammation, and immunomodulation beyond cholesterol-lowering, suggesting a positive impact on various health outcomes. All-cause mortality is a commonly chosen outcome in randomized controlled trials (RCTs) of statins. Nevertheless, the effect of statin treatment on the risk of all-cause mortality remains uncertain since it has usually been evaluated as a secondary outcome or a component of the primary composite outcome. A recent meta-analysis of RCTs also failed to draw a clear conclusion on this issue. Further studies investigating all-cause mortality as a primary endpoint are needed to determine the effect of statins on all-cause mortality from the perspective of evidence-based medicine.
참고문헌 (29)
- Tobert JA, "Lovastatin and beyond : the history of the HMG-CoA reductase inhibitors", Nat Rev Drug Discov, 2, pp.517~526 (2003)
- Collins R, "Interpretation of the evidence for the efficacy and safety of statin therapy", Lancet, 388, pp.2532~2561 (2016)
- Blais JE, "Trends in lipid-modifying agent use in 83 countries", Atherosclerosis, 328, pp.44~51 (2021)
- Wang CY, "Pleiotropic effects of statin therapy : molecular mechanisms and clinical results", Trends Mol Med, 14, pp.37~44 (2008)
- Scandinavian Simvastatin Survival Study Group, "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease : the Scandinavian Simvastatin Survival Study(4S)", Lancet, 344, pp.1383~1389 (1994)
- Long-Term Intervention with Pravastatin in Ischaemic Disease(LIPID)Study Group, "Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels", N Engl J Med, 339, pp.1349~1357 (1998)
- Shepherd J, "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group", N Engl J Med, 333, pp.1301~1307 (1995)
- West of Scotland Coronary Prevention Group, "West of Scotland Coronary Prevention Study : identification of highrisk groups and comparison with other cardiovascular intervention trials", Lancet, 348, pp.1339~1342 (1996)
- Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
- Yusuf S, "Cholesterol lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2021~2031 (2016)
- Byrne P, "Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment : a systematic review and meta-analysis", JAMA Intern Med, 182, pp.474~481 (2022)
- Ray KK, "Statins and all-cause mortality in high-risk primary prevention : a meta-analysis of 11 randomized controlled trials involving 65, 229 participants", Arch Intern Med, 170, pp.1024~1031 (2010)
- Cholesterol Treatment Trialists’(CTT)Collaboration, "Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170, 000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
- Silverman MG, "Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions : a systematic review and meta-analysis", JAMA, 316, pp.1289~1297 (2016)
- 배재현, "Opposing View: A Blind Faith in Meta-Analyses in Academia Could Be a Threat to Public Health", 지질·동맥경화학회지, 11(3), pp.308~313 (2022), 한국지질동맥경화학회[DOI]
- Dobbin KK, "Should we expect all-cause mortality reductions in large screening studies?", Br J Gen Pract, 68, pp.290~291 (2018)
- Sasieni PD, "Should a reduction in all-cause mortality be the goal when assessing preventive medical therapies?", Circulation, 135, pp.1985~1987 (2017)
- Strandberg TE, "Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study(4S)", Lancet, 364, pp.771~777 (2004)
- Nielsen SF, "Statin use and reduced cancer-related mortality", N Engl J Med, 367, pp.1792~1802 (2012)
- Ren QW, "Statin associated lower cancer risk and related mortality in patients with heart failure", Eur Heart J, 42, pp.3049~3059 (2021)
- Kollias A, "Statin use and mortality in COVID-19 patients : updated systematic review and meta-analysis", Atherosclerosis, 330, pp.114~121 (2021)
- Seto AH, "Limitations of long-term mortality as a clinical trial endpoint : time wounds all healing", J Am Coll Cardiol, 76, pp.900~902 (2020)
- Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS) : multicentre randomised placebo-controlled trial", Lancet, 364, pp.685~696 (2004)
- Serruys PW, "Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention : a randomized controlled trial", JAMA, 287, pp.3215~3222 (2002)
- Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355, pp.549~559 (2006)
- ALLHAT Officers, "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care : the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT-LLT)", JAMA, 288, pp.2998~3007 (2002)
- Heart Protection Study Collaborative Group, "MRC", BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals : a randomised placebo-controlled trial, 2002, pp.360, 7~22
- Wanner C, "Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis", N Engl J Med, 353, pp.238~248 (2005)
- Tavazzi L, "Effect of rosuvastatin in patients with chronic heart failure(the GISSI-HF trial) : a randomised, double-blind, placebo-controlled trial", Lancet, 372, pp.1231~1239 (2008)